

Substitute for Form 1449 A & B/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

| | |
|------------------------|-------------------|
| Application Number | 10/519,102 |
| Confirmation Number | NOT YET ASSIGNED |
| Filing Date | December 27, 2004 |
| First Named Inventor | MIKOSHIBA, Imao |
| Art Unit | NOT YET ASSIGNED |
| Examiner Name | NOT YET ASSIGNED |
| Attorney Docket Number | Q85257 |

Sheet 1 of 1

U.S. PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Document Number | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document |
|--------------------|-----------------------|-----------------|--------------------------------------|--------------------------------|---|
| | | Number | Kind Code ² (if known) | | |
| /M.F./ | | US 2003/0040490 | A1 | 02-27-2003 | SUGIYAMA ET AL |
| | | US | | | |
| | | US | | | |
| | | US | | | |
| | | US | | | |
| | | US | | | |
| | | US | | | |
| | | US | | | |
| | | US | | | |

FOREIGN PATENT DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | | | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Translation ⁶ |
|--------------------|-----------------------|---------------------------|---------------------|--------------------------------------|--------------------------------|---|--------------------------|
| | | Country Code ³ | Number ⁴ | Kind Code ⁵ (if known) | | | |
| /M.F./ | | EP | 1 179 342 | A1 | 02-13-2002 | Kissei Pharmaceutical Co., Ltd | English |
| /M.F./ | | JP | 2000-26292 | | 01-25-2000 | Kissei Pharmaceutical Co., Ltd. | Abstract |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

NON PATENT LITERATURE DOCUMENTS

| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published. | Translation ⁶ |
|--------------------|-----------------------|--|--------------------------|
| | | Japanese Journal of Clinical Medicine, 1997, Special extra issue, Vol. 55, pp. 171-179 | No |
| /M.F./ | | Drugs of the Future, 2000, Vol. 20, No. 10, pp. 1034-1042 | English |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|---------------|-----------------|------------|
| Examiner Signature | /Meghan Finn/ | Date Considered | 05/21/2007 |
|--------------------|---------------|-----------------|------------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

| | | | |
|-----------------------------------|---------------------------------------|--|-------------|
| Notice of References Cited | Application/Control No. 10/519,102 | Applicant(s)/Patent Under Reexamination MIKOSHIBA ET AL. | |
| | Examiner Meghan Finn | Art Unit 1609 | Page 1 of 1 |

U.S. PATENT DOCUMENTS

| * | | Document Number Country Code-Number-Kind Code | Date MM-YYYY | Name | Classification |
|---|---|--|-----------------|-----------------|----------------|
| * | A | US-6,133,454 | 10-2000 | Lecouve et al. | 548/515 |
| * | B | US-2003/0073729 | 04-2003 | Kitahara et al. | 514/369 |
| * | C | US-2004/0002544 | 01-2004 | Makino et al. | 514/563 |
| | D | US- | | | |
| | E | US- | | | |
| | F | US- | | | |
| | G | US- | | | |
| | H | US- | | | |
| | I | US- | | | |
| | J | US- | | | |
| | K | US- | | | |
| | L | US- | | | |
| | M | US- | | | |

FOREIGN PATENT DOCUMENTS

| * | | Document Number Country Code-Number-Kind Code | Date MM-YYYY | Country | Name | Classification |
|---|---|--|-----------------|-----------------|-----------------|----------------|
| | N | WO 03/061650 A1 ✓ | 07-2003 | FRANCE | Wuthrich et al. | ----- |
| | O | EP 1179342 A1 ✓ | 02-2002 | European Patent | OUCHI' et al. | ----- |
| | P | WO 00/71117 ✓ | 11-2000 | WIPO | Ouchi et al. | ----- |
| | Q | | | | | |
| | R | | | | | |
| | S | | | | | |
| | T | | | | | |

NON-PATENT DOCUMENTS

| * | | Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages) |
|---|---|--|
| | U | Ohnota et al., Novel Rapid- and Short-Acting Hypoglycemic Agent, a Calcium(2s)-2-benzyl-3-(cis-hexahydro-2-isoindolinylicarbonyl)Propionate(KAD-1229) That Acts on the Sulfonylurea Receptor: Comparison of Effects Between KAD-1229 and Glizalide; 1994, The Journal of Pharmacology and Experimental Therapeutics, 269 (2), p 489-495. ✓ |
| | V | Landgraf et al., A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. 1999, European Journal of Clinical Pharmacology, 55, p 165-171. ✓ |
| | W | Evans et al., Recent Developments and Emerging Therapies for Type 2 Diabetes Mellitus, 1999, Drugs in R&D, 2(2), p. 75-91. ✓ |
| | X | Yamaguchi et al., Preparation of Optically Active Succinic Acid Derivatives. 1. Optical resolution of 2-Benzyl-3-(cis-hexahydroisoindolin-2-ylcarbonyl)-propionic acid, 1997, Chemical and Pharmaceutical Bulletin, 45(9), p. 1518-1520. ✓ |

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.